Celleron Therapeutics
Develops precision cancer drugs and vaccines for patients with advanced, treatment-resistant cancers
Highlights
- New on EvolcAdded 2026-11-08
About Celleron Therapeutics
IngenOx Therapeutics develops precision medicines, including small-molecule drugs and cancer vaccines, for aggressive cancers with limited treatment options. Its pipeline includes therapies for lymphoma, colorectal cancer and liver cancer.
The company advances therapies through clinical and pre-clinical development and pursues strategic collaborations with partners contributing research, development and in-licensing expertise.
Based in Oxford, UK, IngenOx was formed in 2023 through the merger of Oxford University spinouts Celleron Therapeutics and Argonaut Therapeutics. The company’s careers information describes it as a small-medium sized enterprise.
Product: Precision cancer drugs and vaccines developed through in-house discovery and clinical development.
Jobs at Celleron Therapeutics
Leadership
- Nick La Thangue · Chief Executive OfficerSource: company website
More biotech & pharma companies
Cellestial Health
Preclinical small-molecule therapies targeting astrocytic networks for Parkinson’s and other neurological diseasesYoung companyNew on EvolcCellspex
Cell spectroscopy systems and enzyme simulation software for researchers studying mitochondrial bioenergeticsYoung companyNew on EvolcCentauri Therapeutics
Develops Alphamer immunotherapies for infectious diseases, including Gram-negative bacterial infections in high-risk patientsNew on EvolcCerevance
Develops cell-type-specific therapies and drug targets for patients with neurodegenerative, psychiatric and CNS disordersNew on EvolcChemify
Automated chemistry systems that help pharmaceutical and materials partners design and synthesize moleculesNew on EvolcChugai Pharma Europe
European pharmaceutical operations and product support for patients and medical communities across the regionNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.